115 related articles for article (PubMed ID: 31677945)
1. Soluble HLA-G pre-transplant levels to identify the risk for development of infection in heart transplant recipients.
Bortolotti D; Gentili V; Rotola A; Potena L; Rizzo R
Hum Immunol; 2020 Apr; 81(4):147-150. PubMed ID: 31677945
[TBL] [Abstract][Full Text] [Related]
2. Association of soluble human leukocyte antigen-G with acute tubular necrosis in kidney transplant recipients.
Krongvorakul J; Kantachuvesiri S; Ingsathit A; Rattanasiri S; Mongkolsuk T; Kitpoka P; Thammanichanond D
Asian Pac J Allergy Immunol; 2015 Jun; 33(2):117-22. PubMed ID: 26141032
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HLA-G expression in serum and biopsy samples of kidney transplant recipients.
Poláková K; Bandžuchová H; Žilinská Z; Chreňová S; Kuba D; Russ G
Immunobiology; 2015 Apr; 220(4):533-7. PubMed ID: 25468563
[TBL] [Abstract][Full Text] [Related]
4. New markers for predictions of acute and chronic rejection and graft outcomes in kidney transplant recipients; HLA-G gene 3'UTR 14 bp polymorphism and sHLA-G.
Darbas S; Yilmaz VT; Kocak H; Kisaoglu A; Demiryilmaz I; Aydinli B; Arslan HS; Ucar F
Gene; 2021 Jul; 790():145712. PubMed ID: 33984446
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study.
Sarmiento E; Cifrian J; Calahorra L; Bravo C; Lopez S; Laporta R; Ussetti P; Sole A; Morales C; de Pablos A; Jaramillo M; Ezzahouri I; García S; Navarro J; Lopez-Hoyos M; Carbone J
J Heart Lung Transplant; 2018 Aug; 37(8):1001-1012. PubMed ID: 29754764
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Plasma Levels of Soluble HLA-G and HLA-G Genotypes in Kidney Transplant Recipients.
Piancatelli D; Maccarone D; Colanardi A; Sebastiani P; D'Anselmi F; Iesari S; Binda B; Pisani F
Transplant Proc; 2020 Jun; 52(5):1559-1561. PubMed ID: 32217007
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant increase in soluble human leukocyte antigen-G associated with non-severe cardiac allograft vasculopathy.
Blanco-García RM; López-Álvarez MR; Garrido IP; Salgado-Cecilia G; Campillo JA; Bolarín JM; Gimeno L; Muro M; García-Alonso AM; Martínez-Sánchez MV; Bernardo Pisa MV; Soriano-Díaz S; Pascual-Figal DA; Alvarez-López MR; Minguela A
Hum Immunol; 2013 Mar; 74(3):318-24. PubMed ID: 23247208
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study.
Sarmiento E; Jaramillo M; Calahorra L; Fernandez-Yañez J; Gomez-Sanchez M; Crespo-Leiro MG; Paniagua M; Almenar L; Cebrian M; Rabago G; Levy B; Segovia J; Gomez-Bueno M; Lopez J; Mirabet S; Navarro J; Rodriguez-Molina JJ; Fernandez-Cruz E; Carbone J
J Heart Lung Transplant; 2017 May; 36(5):529-539. PubMed ID: 27866926
[TBL] [Abstract][Full Text] [Related]
9. [Serum soluble HLA-G, soluble CD30 is correlated to the time after transplantation in renal transplant recipients].
Jin Z; Xu C; Duan W; Yang J; Tian P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):947-952. PubMed ID: 28712403
[TBL] [Abstract][Full Text] [Related]
10. Donor-derived soluble HLA plasma levels can not be used to monitor graft rejection in heart transplant recipients.
Koelman CA; Vaessen LM; Balk AH; Weimar W; Doxiadis II; Claas FH
Transpl Immunol; 2000 Mar; 8(1):57-64. PubMed ID: 10834611
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
12. Soluble HLA-G levels in heart transplant recipients: Dynamics and correlation with clinical outcomes.
Grille-Cancela Z; Barge-Caballero E; Suárez-Fuentetaja N; Domenech-García N; Paniagua-Martín MJ; Barge-Caballero G; Couto-Mallón D; Enríquez-Vázquez D; Blanco-Canosa P; Pombo-Otero J; Vázquez-Rodríguez JM; Crespo-Leiro MG
Transpl Immunol; 2023 Feb; 76():101771. PubMed ID: 36473577
[TBL] [Abstract][Full Text] [Related]
13. Role of HLA-G as a predictive marker of low risk of chronic rejection in lung transplant recipients: a clinical prospective study.
Brugière O; Thabut G; Krawice-Radanne I; Rizzo R; Dauriat G; Danel C; Suberbielle C; Mal H; Stern M; Schilte C; Pretolani M; Carosella ED; Rouas-Freiss N
Am J Transplant; 2015 Feb; 15(2):461-71. PubMed ID: 25488753
[TBL] [Abstract][Full Text] [Related]
14. Soluble human leukocyte antigen-G (SHLA-G) in Tunisian kidney transplantation.
Bardi R; Sfar I; Aounallah-Skhiri H; Kallala C; Abderrahim E; Ben Abdallah T; Gorgi Y
Arch Inst Pasteur Tunis; 2011; 88(1-4):42-6. PubMed ID: 23461142
[TBL] [Abstract][Full Text] [Related]
15. Circulating and renal expression of HLA-G prevented chronic renal allograft dysfunction in Japanese recipients.
Okushi Y; Okino K; Mukai K; Matsui Y; Hayashi N; Fujimoto K; Adachi H; Yamaya H; Yokoyama H
Clin Exp Nephrol; 2017 Oct; 21(5):932-940. PubMed ID: 28364323
[TBL] [Abstract][Full Text] [Related]
16. Association of HLA-G Polymorphisms in the 3'UTR Region and Soluble HLA-G with Kidney Graft Outcome.
Durmanova V; Bandzuchova H; Zilinska Z; Tirpakova J; Kuba D; Buc M; Polakova K
Immunol Invest; 2019 Aug; 48(6):644-658. PubMed ID: 31094243
[No Abstract] [Full Text] [Related]
17. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
Sheshgiri R; Gustafsson F; Sheedy J; Rao V; Ross HJ; Delgado DH
J Heart Lung Transplant; 2009 Nov; 28(11):1193-7. PubMed ID: 19783164
[TBL] [Abstract][Full Text] [Related]
18. Recipient HLA-G +3142 CC Genotype and Concentrations of Soluble HLA-G Impact on Occurrence of CMV Infection after Living-Donor Kidney Transplantation.
Guberina H; Tomoya Michita R; Dolff S; Bienholz A; Trilling M; Heinemann FM; Horn PA; Kribben A; Witzke O; Rebmann V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29113092
[TBL] [Abstract][Full Text] [Related]
19. Increased prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients.
Lietz K; John R; Kocher A; Schuster M; Mancini DM; Edwards NM; Itescu S
Circulation; 2001 Sep; 104(12 Suppl 1):I177-83. PubMed ID: 11568052
[TBL] [Abstract][Full Text] [Related]
20. sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation.
Luque J; Torres MI; Aumente MD; Lozano JM; García-Jurado G; González R; Alvarez-López MR; Arizón JM; Peña J
Transpl Immunol; 2006 Dec; 17(1):70-3. PubMed ID: 17157221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
